Departments and research groups

Ullern A, Holm K, Andresen NK, Røssevold AH, Bang C, Naume B, Hov JR, Kyte JA (2025)
Gut microbiota diversity is prognostic in metastatic hormone receptor-positive breast cancer patients receiving chemotherapy and immunotherapy
Mol Oncol (in press)
DOI 10.1002/1878-0261.70117, PubMed 40852937

Foldvari Z, Brennan MS, Titov A, Jacobsen SEW, Olweus J (2025)
Targeting the roots of myeloid malignancies with T cell receptors
Nat Rev Cancer (in press)
DOI 10.1038/s41568-025-00857-0, PubMed 40841587

Parissenti AM, Pritzker LB, Dahle MA, Gythfeldt HVL, Masilamani T, Theriault G, St-Onge R, D'costa L, Lingjaerde OC, Haugen MH, Engebraaten O (2025)
High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy
Breast Cancer Res, 27 (1), 143
DOI 10.1186/s13058-025-02092-9, PubMed 40790765

Sagini K, Selvarajah M, Romero S, Bassols-Citores E, Martin-Gracia B, Ramirez-Garrastacho M, Rise F, Endzeliņš E, Sadovska L, Skorinkina D, Boguševiča M, Cešeiko R, Čampa M, Klavina A, Linē A, Llorente A (2025)
The Redox Enzyme Thioredoxin Is Increased in Plasma Extracellular Vesicles From Endurance-Trained Females in Response to Acute Exercise
FASEB J, 39 (16), e70927
DOI 10.1096/fj.202500678R, PubMed 40810354

Ullern A, Holm K, Andresen NK, Røssevold AH, Bang C, Naume B, Hov JR, Kyte JA (2025)
Gut microbiota diversity is prognostic in metastatic hormone receptor-positive breast cancer patients receiving chemotherapy and immunotherapy
Mol Oncol (in press)
DOI 10.1002/1878-0261.70117, PubMed 40852937

Foldvari Z, Brennan MS, Titov A, Jacobsen SEW, Olweus J (2025)
Targeting the roots of myeloid malignancies with T cell receptors
Nat Rev Cancer (in press)
DOI 10.1038/s41568-025-00857-0, PubMed 40841587